CG Oncology, Inc. (CGON) Stock Forecast & Price Target

Compare

207 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CGON Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Oncology, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CGON Stock 12 Month Forecast

Average Price Target

$66.09

▲(65.97% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for CG Oncology, Inc. in the last 3 months. The average price target is $66.09 with a high forecast of $90.00 and a low forecast of $47.00. The average price target represents a 65.97% change from the last price of $39.82.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","56":"$56","91":"$91","38.5":"$38.5","73.5":"$73.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$66.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$47.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,38.5,56,73.5,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.46,32.27076923076923,37.081538461538464,41.892307692307696,46.70307692307692,51.51384615384616,56.324615384615385,61.135384615384616,65.94615384615385,70.75692307692307,75.56769230769231,80.37846153846155,85.18923076923076,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.46,30.431538461538462,33.403076923076924,36.37461538461539,39.34615384615385,42.31769230769231,45.28923076923077,48.260769230769235,51.2323076923077,54.20384615384616,57.175384615384615,60.14692307692308,63.118461538461546,{"y":66.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.46,28.963076923076922,30.466153846153848,31.96923076923077,33.472307692307695,34.97538461538461,36.47846153846154,37.98153846153846,39.48461538461538,40.987692307692306,42.49076923076923,43.99384615384615,45.496923076923075,{"y":47,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$90.00

Average Price Target$66.09

Lowest Price Target$47.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Soumit Roy

JonesTrading

$50→$75

Buy

88.35%

Upside

Reiterated

09/30/25

Analysts Offer Insights on NA Companies: Rubrik, Inc. Class A (NYSE: RBRK) and CG Oncology, Inc. (NASDAQ: CGON)We recently initiated coverage on CGON where we dove into the ongoing clinical trials and raised our average DCF/SOTP NPV/PE price target to $75/share from $50/share; reiterating BUY.

Brian Cheng

J.P. Morgan

$41→$47

Buy

18.03%

Upside

Reiterated

09/26/25

CG Oncology price target raised to $47 from $41 at JPMorganCG Oncology price target raised to $47 from $41 at JPMorgan

Corinne Johnson

Goldman Sachs

$40→$56

Buy

40.63%

Upside

Reiterated

09/22/25

Goldman Sachs Remains a Buy on CG Oncology, Inc. (CGON)

Sam Slutsky

LifeSci Capital

$90

Buy

126.02%

Upside

Reiterated

09/20/25

CG Oncology, Inc. (CGON) Gets a Buy from LifeSci Capitalwe are adjusting our revenue build for cretostimogene and increasing our price target to $90/share from $82/share

Sean Laaman

Morgan Stanley

$56→$79

Buy

98.39%

Upside

Reiterated

09/17/25

CG Oncology price target raised to $79 from $56 at Morgan StanleyCG Oncology price target raised to $79 from $56 at Morgan Stanley

Andres Y. Maldonado

H.C. Wainwright

$75

Buy

88.35%

Upside

Reiterated

09/15/25

Buy Rating for CG Oncology: Creto's Market Potential and Strategic Pricing Flexibility

Kelsey Goodwin

Piper Sandler

$55

Buy

38.12%

Upside

Reiterated

09/10/25

Analysts' Top NA Picks: CG Oncology, Inc. (CGON), Rubrik, Inc. Class A (RBRK)

Alec Stranahan

Bank of America Securities

$62

Buy

55.70%

Upside

Reiterated

09/10/25

Analysts Offer Insights on NA Companies: Reddit Inc Class A (NYSE: RDDT), Solventum Corporation (NYSE: SOLV) and CG Oncology, Inc. (NASDAQ: CGON)

Joshua Schimmer

Cantor Fitzgerald

$75

Buy

88.35%

Upside

Reiterated

09/07/25

Cantor Fitzgerald Keeps Their Buy Rating on CG Oncology, Inc. (CGON)

David Dai

UBS

$60

Buy

50.68%

Upside

Reiterated

08/18/25

Leonid Timashev

RBC Capital

$53

Buy

33.10%

Upside

Reiterated

08/08/25

Wall Street Analysts Are Bullish on Top NA Picks

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

08/08/25

Analysts Conflicted on These NA Names: Tempus AI, Inc. Class A (NASDAQ: TEM) and CG Oncology, Inc. (NASDAQ: CGON)We believe CG could report mature 24-month CRR at SUO in December 2025, where the potential mature 24- month CRR range is between 31% and 39%. Management has emphasized how strongly these AUA data have resonated with physicians, which is fueling enrollment into the company's other NMIBC trials. CG The BLA Ensuring A Broad Label Management plans to initiate the BLA submission process for creto in the Q4. Track designations should allow CG to use a rolling submission, similar to what JNJ did with TAR-200. To begin a rolling submission, the FDA requires upfront alignment on when information for each module is expected. While CG has clarity on the maturity of efficacy metrics, the company is conducting studies to streamline administration (2-step vs. 5-step) and validate creto's stability.

George Farmer

Scotiabank

$23

Hold

-42.24%

Downside

Reiterated

05/14/25

Scotiabank Reaffirms Their Hold Rating on CG Oncology, Inc. (CGON)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Soumit Roy

JonesTrading

$50→$75

Buy

88.35%

Upside

Reiterated

09/30/25

Brian Cheng

J.P. Morgan

$41→$47

Buy

18.03%

Upside

Reiterated

09/26/25

CG Oncology price target raised to $47 from $41 at JPMorganCG Oncology price target raised to $47 from $41 at JPMorgan

Corinne Johnson

Goldman Sachs

$40→$56

Buy

40.63%

Upside

Reiterated

09/22/25

Goldman Sachs Remains a Buy on CG Oncology, Inc. (CGON)

Sam Slutsky

LifeSci Capital

$90

Buy

126.02%

Upside

Reiterated

09/20/25

CG Oncology, Inc. (CGON) Gets a Buy from LifeSci Capitalwe are adjusting our revenue build for cretostimogene and increasing our price target to $90/share from $82/share

Sean Laaman

Morgan Stanley

$56→$79

Buy

98.39%

Upside

Reiterated

09/17/25

CG Oncology price target raised to $79 from $56 at Morgan StanleyCG Oncology price target raised to $79 from $56 at Morgan Stanley

Andres Y. Maldonado

H.C. Wainwright

$75

Buy

88.35%

Upside

Reiterated

09/15/25

Buy Rating for CG Oncology: Creto's Market Potential and Strategic Pricing Flexibility

Kelsey Goodwin

Piper Sandler

$55

Buy

38.12%

Upside

Reiterated

09/10/25

Analysts' Top NA Picks: CG Oncology, Inc. (CGON), Rubrik, Inc. Class A (RBRK)

Alec Stranahan

Bank of America Securities

$62

Buy

55.70%

Upside

Reiterated

09/10/25

Analysts Offer Insights on NA Companies: Reddit Inc Class A (NYSE: RDDT), Solventum Corporation (NYSE: SOLV) and CG Oncology, Inc. (NASDAQ: CGON)

Joshua Schimmer

Cantor Fitzgerald

$75

Buy

88.35%

Upside

Reiterated

09/07/25

Cantor Fitzgerald Keeps Their Buy Rating on CG Oncology, Inc. (CGON)

David Dai

UBS

$60

Buy

50.68%

Upside

Reiterated

08/18/25

Leonid Timashev

RBC Capital

$53

Buy

33.10%

Upside

Reiterated

08/08/25

Wall Street Analysts Are Bullish on Top NA Picks

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

08/08/25

George Farmer

Scotiabank

$23

Hold

-42.24%

Downside

Reiterated

05/14/25

Scotiabank Reaffirms Their Hold Rating on CG Oncology, Inc. (CGON)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CG Oncology, Inc.

1 Month

xxx

Success Rate

4/5 ratings generated profit

Average Return

+10.42%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +10.42% per trade.

3 Months

xxx

Success Rate

4/5 ratings generated profit

Average Return

+19.12%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +19.12% per trade.

1 Year

Sean LaamanMorgan Stanley

Success Rate

5/5 ratings generated profit

Average Return

+43.18%

reiterated a buy rating 18 days ago

Copying Sean Laaman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +43.18% per trade.

2 Years

xxx

Success Rate

5/5 ratings generated profit

Average Return

+43.18%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +43.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CGON Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CGON has received 26 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. CGON average Analyst price target in the past 3 months is 66.09.

Each month's total comprises the sum of three months' worth of ratings.

CGON Financial Forecast

CGON Earnings Forecast

Next quarter’s earnings estimate for CGON is -$0.56 with a range of -$0.63 to -$0.49. The previous quarter’s EPS was -$0.54. CGON beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year CGON has Outperformed its overall industry.

CGON Sales Forecast

Next quarter’s sales forecast for CGON is $73.00K with a range of $0.00 to $600.00K. The previous quarter’s sales results were $0.00. CGON beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year CGON has Outperformed its overall industry.

CGON Stock Forecast FAQ

What is CGON’s average 12-month price target, according to analysts?

Based on analyst ratings, CG Oncology, Inc.’s 12-month average price target is 66.09.

What is CGON’s upside potential, based on the analysts’ average price target?

CG Oncology, Inc. has 65.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CGON a Buy, Sell or Hold?

CG Oncology, Inc. has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is CG Oncology, Inc.’s price target?

The average price target for CG Oncology, Inc. is 66.09. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $90.00 ,the lowest forecast is $47.00. The average price target represents 65.97% Increase from the current price of $39.82.

What do analysts say about CG Oncology, Inc.?

CG Oncology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of CGON?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

CG Oncology, Inc. (CGON) Stock Forecast & Price Target

CGON Analyst Ratings

CGON Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CG Oncology, Inc.

CGON Analyst Recommendation Trends

CGON Financial Forecast

CGON Earnings Forecast

CGON Sales Forecast

CGON Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts